Biggest News Aggregation in the World
📰 Cell Cycle News

Page 5 - Cell Cycle News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Cell Cycle. Real-time updates on events, politics, business and more.

Stay Updated with Latest News

Get breaking news updates delivered to your inbox

Browse All News →

Addition of capivasertib to fulvestrant doubles progression-free survival in HR-positive breast cancer patients

In patients with hormone receptor (HR)-positive, HER2-negative tumors resistant to aromatase inhibitors, addition of the investigational AKT inhibitor capivasertib to fulvestrant (Faslodex) doubled the median progression-free survival compared with placebo plus fulvestrant in the phase III CAPItello-291 clinical trial, according to results presented at the San Antonio Breast Cancer Symposium, held December 6-10, 2022.
San Antonio United States City Of United Kingdom Nicholas Turner Emily Henderson

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science